Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

Prespecified subgroup analyses showed that primary surgery conferred greater benefits for patients with stage III disease and ...

New research suggests that an antibody-drug conjugate may offer practice-changing, patient-friendly treatment of blastic ...

CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; ...

Five early-career Fred Hutch/UW researchers received prestigious Young Investigator Awards from Conquer Cancer, the ASCO Foundation during this year's annual meeting of the American Society of ...

A recent study reveals rising early-onset colorectal cancer rates, highlighting disparities and the need for improved ...

Colorectal cancer offered the earliest window into the trend of increased cancer incidence among those younger than age 50.

Karen Eubanks Jackson has reshaped the conversation around breast cancer for Black women in America—and now, with the ASCO ...

New research presented at the 2025 American Society for Clinical Oncology’s (ASCO) annual meeting has shed light on the ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

Alphamab Oncology (stock code: 9966.HK) announced that multiple clinical data updates for anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 were presented as posters at the 2025 Annual ...